Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Tenax Therapeutics is a biotechnology business based in the US. Tenax Therapeutics shares (TENX) are listed on the NASDAQ and all prices are listed in US Dollars. Tenax Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.52 |
|---|---|
| 52-week range | $0.45 - $17.00 |
| 50-day moving average | $1.46 |
| 200-day moving average | $4.07 |
| Wall St. target price | $62.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-6.34 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.515 from 2023-03-17
| 1 week (2023-03-14) | -5.50% |
|---|---|
| 1 month (2023-02-21) | -34.73% |
| 3 months (2022-12-21) | 284.04% |
| 6 months (2022-09-21) | 165.46% |
| 1 year (2022-03-17) | -14.20% |
|---|---|
| 2 years (2021-03-19) | -75.82% |
| 3 years (2020-03-20) | 3.23% |
| 5 years (2018-03-20) | 150.6 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -96.24% |
| Return on equity TTM | -209.24% |
| Profit margin | 0% |
| Book value | $2.64 |
| Market capitalisation | $4.5 million |
TTM: trailing 12 months
We're not expecting Tenax Therapeutics to pay a dividend over the next 12 months.
Tenax Therapeutics's shares were split on a 1:20 basis on 4 January 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tenax Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Tenax Therapeutics shares which in turn could have impacted Tenax Therapeutics's share price.
Over the last 12 months, Tenax Therapeutics's shares have ranged in value from as little as $0.452 up to $17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tenax Therapeutics's is 2.1529. This would suggest that Tenax Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tenax Therapeutics, Inc. , a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.